These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20531222)

  • 21. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.
    Kasper S; Iglesias-García C; Schweizer E; Wilson J; DuBrava S; Prieto R; Pitman VW; Knapp L
    Int J Neuropsychopharmacol; 2014 May; 17(5):685-95. PubMed ID: 24351233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study.
    Elger CE; Brodie MJ; Anhut H; Lee CM; Barrett JA
    Epilepsia; 2005 Dec; 46(12):1926-36. PubMed ID: 16393158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregabalin-associated elevation of clozapine serum levels.
    Gahr M; Schmid MM; Schönfeldt-Lecuona C
    Pharmacopsychiatry; 2012 Nov; 45(7):297-9. PubMed ID: 22473300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
    Behdani F; Hebrani P; Rezaei Ardani A; Rafee E
    Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study.
    Karaiskos D; Pappa D; Tzavellas E; Siarkos K; Katirtzoglou E; Papadimitriou GN; Politis A
    Int J Geriatr Psychiatry; 2013 Jan; 28(1):100-5. PubMed ID: 22431439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregabalin in the discontinuation of long-term benzodiazepines' use.
    Oulis P; Konstantakopoulos G; Kouzoupis AV; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kontoangelos KA; Papadimitriou GN
    Hum Psychopharmacol; 2008 Jun; 23(4):337-40. PubMed ID: 18348245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of augmentation with moclobemide on symptoms of schizophrenia.
    Silver H; Aharon N; Hausfater N; Jahjah N
    Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
    Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
    Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice.
    Bobes J; Rubio G; Terán A; Cervera G; López-Gómez V; Vilardaga I; Pérez M
    Eur Psychiatry; 2012 May; 27(4):301-7. PubMed ID: 21334859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia.
    Arnold LM; Leon T; Whalen E; Barrett J
    Psychosomatics; 2010; 51(6):489-97. PubMed ID: 21051680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use.
    Rubio G; Bobes J; Cervera G; Terán A; Pérez M; López-Gómez V; Rejas J
    Eur Addict Res; 2011; 17(5):262-70. PubMed ID: 21701173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy of pregabalin in generalized anxiety disorder.
    Feltner D; Wittchen HU; Kavoussi R; Brock J; Baldinetti F; Pande AC
    Int Clin Psychopharmacol; 2008 Jan; 23(1):18-28. PubMed ID: 18090504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
    Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
    J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
    Anand R; Geffen Y; Vasile D; Dan I
    Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study.
    Pae CU; Marks DM; Han C; Masand PS; Patkar AA
    Int Clin Psychopharmacol; 2009 Jan; 24(1):29-33. PubMed ID: 19060720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
    J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.
    Kremer I; Vass A; Gorelik I; Bar G; Blanaru M; Javitt DC; Heresco-Levy U
    Biol Psychiatry; 2004 Sep; 56(6):441-6. PubMed ID: 15364042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.